APRE
What one share of Aprea Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
Aprea Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.60 |
|---|---|
| Cash and investments | $3.33 |
| Book value | $3.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$263.48 | — | −$242.87 | — | −$620.35 |
| 2018 | — | −$269.04 | $0.06 | −$264.28 | — | −$890.39 |
| 2019 | — | −$93.49 | $0.10 | −$89.10 | — | — |
| 2020 | — | −$50.61 | $0.02 | −$39.58 | — | $73.06 |
| 2021 | — | −$34.88 | — | −$35.41 | — | $45.30 |
| 2022 | — | −$67.99 | — | −$15.09 | — | $9.66 |
| 2023 | — | −$3.95 | $0.03 | −$3.39 | — | $4.54 |
| 2024 | — | −$2.35 | $0.00 | −$2.46 | — | $3.52 |
| 2025 | — | −$1.93 | — | −$1.97 | — | $1.52 |